Rapacuronium bromide
This article relies largely or entirely on a single source. (November 2007) |
Clinical data | |
---|---|
Other names | [(2S, 3S, 5S, 8R, 9S, 10S, 13S, 14S, 16S, 17S)-3-acetyloxy-10,13-dimethyl-2-(1-piperidyl)-16-(1-prop-2-enyl-3,4,5,6-tetrahydro-2H-pyridin-1-yl)-2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,11 ,12 ,14, 15, 16, 17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]propanoate |
Routes of administration | Intravenous |
ATC code |
|
Legal status | |
Legal status |
|
CYP system not involved | |
Elimination half-life | 141 minutes (mean) |
Excretion | Renal and fecal |
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Rapacuronium bromide (brand name Raplon) is a rapidly acting, non-depolarizing
intensive care. As a non-depolarizing agent it did not cause initial stimulation of muscles before weakening them.[1]
Due to risk of fatal
Organon on March 27, 2001, less than 2 years after its FDA approval in 1999.[2]
References
- S2CID 46984904.
- Organon International) (27 March 2001). "Voluntary Market Withdrawal" (PDF). Food and Drug Administration. Archived from the original(PDF) on 24 September 2008.